Device Closure of a Large Atrial Septal Defect in a Patient with Severe Pulmonary Arterial Hypertension after 1 Year Use of an Oral Endothelin Receptor Antagonist
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The presence of severe pulmonary arterial hypertension (PAH) in patients with atrial septal defect (ASD) is still thought to preclude shunt closure, although there are several reports of good clinical outcomes after vasodilator therapy. We report the case of a young woman with ASD and severe PAH who was able to successfully undergo percutaneous shunt closure following 1 year use of the oral endothelin receptor antagonist, bosentan.
Abstract
The presence of severe pulmonary arterial hypertension (PAH) in patients with atrial septal defect (ASD) is still thought to preclude shunt closure, although there are several reports of good clinical outcomes after vasodilator therapy. We report the case of a young woman with ASD and severe PAH who was able to successfully undergo percutaneous shunt closure following 1 year use of the oral endothelin receptor antagonist, bosentan.
참고문헌 (12)
- Konstantinides S, "A comparison of surgical and medical therapy for atrial septal defect in adults", N Engl J Med, 333, pp.469~473 (1995)
- Besterman E, "Atrial septal defect with pulmonary hypertension", Br Heart J, 23, pp.587~598 (1961)
- Therrien J, "Canadian Cardiovascular Society Consensus Conference 2001 update: Recommendations for the Management of Adults with Congenital Heart Disease-- Part II", Can J Cardiol, 17, pp.1029~1050 (2001)
- Schwerzmann M, "Atrial septal defect closure in a patient with “irreversible” pulmonary hypertensive arteriopathy", Int J Cardiol, 110, pp.104~107 (2006)
- Kim YH, "Repair of atrial septal defect with Eisenmenger syndrome after long-term sildenafil therapy", Ann Thorac Surg, 89, pp.1629~1630 (2010)
- 박용규, "Transient Use of Oral Bosentan Can Be an Additional Option to Reduce Pulmonary Arterial Hypertension in a Patient with Severe Pulmonary Arterial Hypertension Associated with Atrial Septal Defect", Journal of Cardiovascular Ultrasound, 19(3), pp.159~162 (2011), 한국심초음파학회
- Dimopoulos K, "Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy", Int J Cardiol, 129, pp.163~171 (2008)
- Balint OH, "Outcomes in patients with pulmonary hypertension undergoing percutaneous atrial septal defect closure", Heart, 94, pp.1189~1193 (2008)
- Yamauchi H, "Reduction in recalcitrant pulmonary hypertension after operation for atrial septal defect", Ann Thorac Surg, 72, pp.905~906 (2001)
- 정조원, "Pulmonary Arterial Hypertension of Congenital Heart Diseases:From Reversible Pulmonary Hypertension to Eisenmenger Syndrome", Korean Circulation Journal, 37(7), pp.287~297 (2007), 대한심장학회
- Diller GP, "Pulmonary vascular disease in adults with congenital heart disease", Circulation, 115, pp.1039~1050 (2007)
- Galiè N, "Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study", Circulation, 114, pp.48~54 (2006)